Wedbush Issues Positive Outlook for BCRX Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Wedbush increased their Q2 2025 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Monday, May 5th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $0.00 per share for the quarter, up from their prior forecast of ($0.03). Wedbush currently has a "Outperform" rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' FY2025 earnings at $0.11 EPS, Q1 2026 earnings at $0.11 EPS, Q2 2026 earnings at $0.14 EPS, Q4 2026 earnings at $0.17 EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.68 EPS.

Several other analysts have also weighed in on the company. Needham & Company LLC lifted their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. StockNews.com raised shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. HC Wainwright reissued a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Trading Up 0.6 %

BCRX stock traded up $0.06 during trading on Thursday, reaching $9.98. 7,606,302 shares of the stock were exchanged, compared to its average volume of 2,989,382. BioCryst Pharmaceuticals has a twelve month low of $5.34 and a twelve month high of $11.11. The company has a market capitalization of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08. The stock has a 50 day simple moving average of $7.87 and a 200-day simple moving average of $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. BioCryst Pharmaceuticals's revenue was up 40.8% on a year-over-year basis. During the same quarter last year, the company earned $0.28 EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BCRX. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. New Age Alpha Advisors LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter worth about $62,000. R Squared Ltd grew its holdings in BioCryst Pharmaceuticals by 84.2% during the 1st quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company's stock worth $88,000 after acquiring an additional 5,335 shares during the last quarter. Jupiter Asset Management Ltd. increased its position in BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after acquiring an additional 971,040 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of BioCryst Pharmaceuticals by 314.8% in the first quarter. XTX Topco Ltd now owns 87,389 shares of the biotechnology company's stock worth $655,000 after acquiring an additional 66,320 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.